Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial

Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate (PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial inhibitor of TNAP. The aim was to investigate whether lansoprazole increases plasma PPi levels in subjects w...

Descripción completa

Detalles Bibliográficos
Autores: Murcia Casas, Belén, Carrillo Linares, Juan Luis, Baquero Aranda, Isabel, Rioja Villodres, José, Merino Bohórquez, Vicente, González Jiménez, Andrés, Rico Corral, Miguel Ángel, Valdivielso, Pedro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/156676
Acceso en línea:https://hdl.handle.net/11441/156676
https://doi.org/10.3390/ijms24054899
Access Level:acceso abierto
Palabra clave:pseudoxanthoma elasticum
inorganic pyrophosphate
lansoprazole
tissue-nonspecific alkaline phosphatase
id ES_e43f3ea2809da0f5ed4445c70db2d28f
oai_identifier_str oai:idus.us.es:11441/156676
network_acronym_str ES
network_name_str España
repository_id_str
spelling Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trialMurcia Casas, BelénCarrillo Linares, Juan LuisBaquero Aranda, IsabelRioja Villodres, JoséMerino Bohórquez, VicenteGonzález Jiménez, AndrésRico Corral, Miguel ÁngelValdivielso, Pedropseudoxanthoma elasticuminorganic pyrophosphatelansoprazoletissue-nonspecific alkaline phosphatasePseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate (PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial inhibitor of TNAP. The aim was to investigate whether lansoprazole increases plasma PPi levels in subjects with PXE.We conducted a 2 2 randomized, double-blind, placebo-controlled crossover trial in patients with PXE. Patients were allocated 30 mg/day of lansoprazole or a placebo in two sequences of 8 weeks. The primary outcome was the differences in plasma PPi levels between the placebo and lansoprazole phases. 29 patients were included in the study. There were eight drop-outs due to the pandemic lockdown after the first visit and one due to gastric intolerance, so twenty patients completed the trial. A generalized linear mixed model was used to evaluate the effect of lansoprazole. Overall, lansoprazole increased plasma PPi levels from 0.34 0.10 M to 0.41 0.16 M (p = 0.0302), with no statistically significant changes in TNAP activity. There were no important adverse events. 30 mg/day of lansoprazole was able to significantly increase plasma PPi in patients with PXE; despite this, the study should be replicated with a large number of participants in a multicenter trial, with a clinical end point as the primary outcome.MDPIFarmacologíaMedicinaAsociación Española de Afectados por PXE2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/156676https://doi.org/10.3390/ijms24054899reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésInternational Journal of Molecular Sciences, 24 (5), 4899.https://doi.org/10.3390/ijms24054899info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1566762026-06-17T12:51:07Z
dc.title.none.fl_str_mv Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
title Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
spellingShingle Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
Murcia Casas, Belén
pseudoxanthoma elasticum
inorganic pyrophosphate
lansoprazole
tissue-nonspecific alkaline phosphatase
title_short Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
title_full Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
title_fullStr Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
title_full_unstemmed Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
title_sort Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial
dc.creator.none.fl_str_mv Murcia Casas, Belén
Carrillo Linares, Juan Luis
Baquero Aranda, Isabel
Rioja Villodres, José
Merino Bohórquez, Vicente
González Jiménez, Andrés
Rico Corral, Miguel Ángel
Valdivielso, Pedro
author Murcia Casas, Belén
author_facet Murcia Casas, Belén
Carrillo Linares, Juan Luis
Baquero Aranda, Isabel
Rioja Villodres, José
Merino Bohórquez, Vicente
González Jiménez, Andrés
Rico Corral, Miguel Ángel
Valdivielso, Pedro
author_role author
author2 Carrillo Linares, Juan Luis
Baquero Aranda, Isabel
Rioja Villodres, José
Merino Bohórquez, Vicente
González Jiménez, Andrés
Rico Corral, Miguel Ángel
Valdivielso, Pedro
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Farmacología
Medicina
Asociación Española de Afectados por PXE
dc.subject.none.fl_str_mv pseudoxanthoma elasticum
inorganic pyrophosphate
lansoprazole
tissue-nonspecific alkaline phosphatase
topic pseudoxanthoma elasticum
inorganic pyrophosphate
lansoprazole
tissue-nonspecific alkaline phosphatase
description Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate (PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial inhibitor of TNAP. The aim was to investigate whether lansoprazole increases plasma PPi levels in subjects with PXE.We conducted a 2 2 randomized, double-blind, placebo-controlled crossover trial in patients with PXE. Patients were allocated 30 mg/day of lansoprazole or a placebo in two sequences of 8 weeks. The primary outcome was the differences in plasma PPi levels between the placebo and lansoprazole phases. 29 patients were included in the study. There were eight drop-outs due to the pandemic lockdown after the first visit and one due to gastric intolerance, so twenty patients completed the trial. A generalized linear mixed model was used to evaluate the effect of lansoprazole. Overall, lansoprazole increased plasma PPi levels from 0.34 0.10 M to 0.41 0.16 M (p = 0.0302), with no statistically significant changes in TNAP activity. There were no important adverse events. 30 mg/day of lansoprazole was able to significantly increase plasma PPi in patients with PXE; despite this, the study should be replicated with a large number of participants in a multicenter trial, with a clinical end point as the primary outcome.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/156676
https://doi.org/10.3390/ijms24054899
url https://hdl.handle.net/11441/156676
https://doi.org/10.3390/ijms24054899
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv International Journal of Molecular Sciences, 24 (5), 4899.
https://doi.org/10.3390/ijms24054899
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422574527578112
score 15,811543

Similares en LA Referencia